Intervacc announces changes in the Nomination Committee

Stockholm, March 17, 2025 – The composition of the Nomination Committee in Intervacc AB (publ) (“Intervacc”) has changed due to the recently completed rights issue. The members of the Nomination Committee have been appointed in accordance with the principles for appointing the Nomination Committee in Intervacc that were adopted at the Annual General Meeting on June 14, 2022.

After the changes, the Nomination Committee in Intervacc before the Annual General Meeting 2025 has the following composition:

• Staffan Lindstrand appointed by Healthcap.
• Magnus Lundberg, appointed by ownership group consisting of Håkan Björklund and Magnus Lundberg
• Sven Nyman appointed by SN-P Särskilda.

The chairman of the Nomination Committee is appointed in connection with the first meeting.

The Nomination Committee together represent approximately 33 percent of the number of shares and votes in the company based on the shareholder information as of March 5, 2025.

The Nomination Committee’s task is to, before the Annual General Meeting 2025, prepare and submit proposals for election of the chairman of the board and the other members of the board, board remuneration and any other remuneration to the members of the board as well as the election of and remuneration to auditors.

Shareholders who wish to submit proposals to the Nomination Committee can do so by sending an e-mail to [email protected] (heading – “Nomination Committee”) or by letter posted to Intervacc AB (publ), Attn: Intervacc Nomination Committee, Box 112, SE-129 22 Stockholm, Sweden.

For more information please contact:  

Jonas Sohlman, CEO

Phone: +46 (0)8 120 10 600

E-mail: [email protected]

The information was submitted for publication, through the agency of the contact person set out above on March 17, 2025, 17.40 CET.

About Intervacc

Intervacc AB is a Swedish company within animal health developing vaccines for animals. The Company's vaccine and vaccine candidates are based on several years of research at Karolinska Institutet and Swedish University of Agricultural Sciences where the foundation was laid for the Company´s research and development work. The Intervacc share has been listed on the Nasdaq First North Growth Market since April 2017 with Eminova Fondkommission AB as Certified Adviser.

Contact information for Certified Adviser

Eminova Fondkommission AB

E-mail: [email protected], Phone: +46 (0)8 – 684 211 10